Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of Mecbotamab-vedotin in combination with Opdivo® (nivolumab)

Trial Profile

A clinical trial of Mecbotamab-vedotin in combination with Opdivo® (nivolumab)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 17 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 17 Jan 2022 New trial record
  • 10 Jan 2022 According to a BioAtla media release, company has entered into a clinical collaboration with Bristol Myers Squibb for this trial. BioAtla will serve as the study sponsor and will be responsible for costs associated with the trial execution. Bristol Myers Squibb will provide Opdivo clinical drug supply for the study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top